Oncology Central

ASCO18: Day 3 update

0

Today at our booth

The third day was one of the most days of the conference for the Oncology Central team as we eagerly waited to discover all the data from the plenary session. We have collated our highlights, let us know your thoughts in the comments below or on social media.

Remember you can find us at booth #4040, or follow our Twitter updates @OncologyCentral.

Video highlights

Tomorrow’s key talk to attend

antibody_immunotherapy

CheckMate 227 study on Monday 4 June, 15:12–15:24 in Hall B1.

Today’s news

Early-stage breast cancer patients could be spared chemotherapy, TAILORx trial shows

Results from the Phase III TAILORx clinical trial have indicated that most women with hormone receptor-positive, HER2-negative, axillary node-negative early-stage breast cancer and a midrange score on a 21-tumor gene expression assay do not need chemotherapy after surgery.

Read the full story.

Is surgery necessary for advanced kidney cancer?

Individuals with advanced kidney cancer can avoid a nephrectomy without compromising their survival, according to results from  the CARMENA trial.

Discover more about this study.

KEYNOTE-042: pembrolizumab may be more effective than chemo for advanced NSCLC

Results of the KEYNOTE-042 study have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.

Full story here.

Practice-changing breakthrough made for rare cancer

A novel chemotherapy strategy has improved cure rates for a rare cancer of the muscle tissue, termed rhabdomyosarcoma.

Read the full story.

Best of social media #ASCO18


Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.